Healthcare Industry News: Coronado Biosciences
News Release - January 3, 2008
Coronado Builds Core Management TeamSAN DIEGO, Jan. 3 (HSMN NewsFeed) -- Coronado Biosciences Inc. today announced the appointments of Elizabeth Moore as senior vice president, regulatory affairs, and Linda Rogers as vice president, clinical operations.
Moore will be responsible for developing regulatory strategies and designing programs for Coronado's oncology drug pipeline. Rogers will responsible for managing Coronado's clinical trial programs.
"We're focused on making existing cancer therapies better while managing scientific, financial and regulatory risk associated with drug development," said RJ Tesi, M.D., president and CEO of Coronado. "Elizabeth and Linda have joined Coronado at a time that we're preparing to begin clinical trials with four of our product candidates. These two experienced biotech executives will be integral parts of our management team and will contribute to the success of our programs."
Moore has more than 20 years of experience in the biotechnology and pharmaceutical industries and has worked for governmental regulatory agencies. Prior to joining Coronado, she was vice president of regulatory affairs for Paramount BioSciences LLC, a global drug development and investment firm, for which she led the development of regulatory strategies for many of Paramount's start-up companies. Before this, she was vice president of regulatory affairs at TRACON Pharmaceuticals Inc., where she developed and managed the company's regulatory affairs function.
Moore was also the vice president of regulatory affairs for Saldemix Inc., where she provided strategic regulatory support and guidance for the successful development and commercialization of three oncology products. In addition, she has held regulatory positions with Pfizer Global Research and Development and Agouron Pharmaceuticals Inc. and worked in regulatory affairs positions with branches of the National Institutes of Health, including the National Cancer Institute. She holds a master's degree in administrative science from The Johns Hopkins University and a bachelor's degree in pharmacy from the University of Georgia.
Rogers has more than 30 years of experience in clinical research and development. Prior to joining Coronado, she was the senior director of global clinical operations with Cellerant Therapeutics Inc., where she facilitated the preparation of three pre-IND submissions, participated in meetings with the FDA, developed departmental protocols and oversaw clinical research organization activities. Before this, she held positions of increasing responsibility with SangStat Medical Corp., where she established processes and procedures to transition the company from a start-up to a development- stage company.
Rogers was also the director of clinical operations for Pharmacyclics Inc., where she managed the department and created processes and procedure for oncology and cardiovascular clinical trials. In addition, she held positions of increasing responsibility with BERLEX Laboratories, Genetech Inc., Searle Pharmaceuticals and Abbott Laboratories. She holds a master's degree in management from John F. Kennedy University School of Management and a bachelor's degree in health science from Barat College.
About Coronado Biosciences Inc.
Coronado Biosciences Inc. is a clinical stage biopharmaceutical company that is focused on changing cancer care by improving current therapies. The company's pipeline consists of both clinical and pre-clinical compounds that will offer unique options to physicians and patients. By mitigating scientific, development and financial risk, the company increases the likelihood of developing marketable drugs with the potential for broad indications. For more information, call (858) 731-8517.
Source: Coronado Biosciences
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.